Platelet Rich Plasma in Corneal Surface Diseases

• Status: Not yet recruiting
• Trial end date: 2023-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The Aim of the study is to evaluate the efficacy of platelet rich plasma eye drops in the management of different corneal surface disorders.

PRP is a blood sample with a concentrated platelet count, and numerous growth factors that are associated with conjunctival and corneal wound healing process. which is an important advantage over other products. PRP eye drops recently are proving to be an effective and potent therapeutic approach to promote corneal wound re-epithelization and promote ocular surface regeneration in different pathological conditions.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Ophthalmic Solutions

Criteria

Inclusion Criteria:

1. Persistent epithelial defects (Exposure keratopathy, Post infectious keratitis).

2. Dry eye disease.

Exclusion Criteria:

1. Active ocular infection or inflammation.

2. Patients will be withdrawn if allergic or adverse side effects develop.

3. Pregnancy or breast feeding.

4. The use of systemic antiplatelet or anticoagulant.

5. Uncontrolled systemic diseases

6. Non-compliance with the study protocol.

7. Positive HIV, HBV, HCB or Syphilis.

8. Anemia (less than 10 g/dl of HGB, platelet count less than 105/ul).